盘前时段
|
||||
|
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.39/-0.47
|
企业价值
22.25M
|
资产负债 |
每股账面净值
0.32
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
0.69
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比较之报价最少15分钟延迟
业务概览
|
|||
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consistsof nafamostat product candidates and pre-filled syringe product candidates. |